rmed-8k_20221129.htm

0001564590-22-038507.txt : 20221129 0001564590-22-038507.hdr.sgml : 20221129 20221129070147 ACCESSION NUMBER: 0001564590-22-038507 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20221129 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221129 DATE AS OF CHANGE: 20221129 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ra Medical Systems, Inc. CENTRAL INDEX KEY: 0001716621 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 383661826 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38677 FILM NUMBER: 221428285 BUSINESS ADDRESS: STREET 1: 5857 OWENS DRIVE, SUITE 300 CITY: CARLSBAD STATE: CA ZIP: 92009 BUSINESS PHONE: (760) 804-1648 MAIL ADDRESS: STREET 1: 5857 OWENS DRIVE, SUITE 300 CITY: CARLSBAD STATE: CA ZIP: 92009 8-K 1 rmed-8k_20221129.htm 8-K rmed-8k_20221129.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

November 29, 2022

Ra Medical Systems, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-38677

38-3661826

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

2070 Las Palmas Drive

Carlsbad, California 92011

(Address of principal executive offices, including zip code)

(760) 804-1648

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☒	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☒	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001	RMED	NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

Press Release

On November 29, 2022, Ra Medical Systems, Inc (“Ra Medical” or the “Company”). and Catheter Precision, Inc. (“Catheter” or “Catheter Precision”) issued a joint press release announcing the completion of more than 20 procedures at NYU Langone Hospital utilizing Catheter’s VIVO^TM System that enables physicians to identify the origin of arrhythmias pre-procedure. A copy of this press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

Additional Information and Where to Find It

On September 12, 2022, Ra Medical announced entering into an Agreement and Plan of Merger (the “Merger Agreement”) with privately held Catheter Precision, Inc. (“Catheter”), a medical device and technology company focused in the field of cardiac electrophysiology. Under the terms of the Merger Agreement, Catheter will become a wholly owned subsidiary of Ra Medical in a stock-for-stock reverse merger transaction (the “Merger”). If completed, the Merger will result in a combined publicly traded company that will focus on the cardiac electrophysiology market, one of the most robust and growing areas of medical devices.

The Merger is currently expected to close before the end of 2022, subject to satisfying certain closing conditions, including the receipt of shareholder approval by both companies. The descriptions of the Merger, the proposals to be voted on in connection with the Merger at the Ra Medical Special Meeting of Stockholders, Catheter and the other transactions and matters contemplated thereby that are referenced herein do not purport to be complete and are qualified in their entirety by reference to the Company’s Reports filed with the Securities and Exchange Commission (“SEC”), including the Current Reports on Form 8-K filed on September 12, 2022 and September 2, 2022, the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2022 and any prior or subsequent reports on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to time and available on the SEC website, as well as the Company’s preliminary proxy statement relating to the Merger with Catheter Precision that was filed with the SEC on September 23, 2022, as further described below.

This communication relates to the proposed Merger involving Catheter and the Company and may be deemed to be solicitation material in respect of the proposed transaction. In connection with the proposed Merger between Catheter and the Company, on September 23, 2022, the Company filed a preliminary proxy statement with the SEC and intends to file a definitive proxy statement (the “Definitive Proxy”) to call, give notice of and hold a meeting of its stockholders to vote to approve, among other matters, (a) the Merger, and (b) the issuance of the shares of the Ra Medical Common Stock to be issued pursuant to the terms of the Merger Agreement. This communication is not a substitute for the Definitive Proxy or any other documents that the Company may file with the SEC or send to the Company’s stockholders in connection with the proposed transaction. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITYHOLDERS ARE URGED TO READ THE DEFINITIVE AND ALL OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. INVESTORS AND SECURITY HOLDERS MAY OBTAIN FREE COPIES OF THESE DOCUMENTS (WHEN THEY ARE AVAILABLE) AND OTHER RELATED DOCUMENTS FILED WITH THE SEC AT THE SEC’S WEBSITE AT WWW.SEC.GOV, ON RA MEDICAL’S INVESTOR RELATIONS WEB PAGE AT HTTPS://IR.RAMED.COM/.

Catheter Precision also intends to furnish an information statement and consent solicitation to its stockholders in connection with the proposed Merger as part of the PPM/Joint Information Statement (as defined below). The only matters that the Company is seeking approval for at the Special Meeting of Stockholders are the matters that are set forth in the Definitive Proxy.

The Definitive Proxy and PPM/Joint Information Statement contain or will contain important information about Catheter Precision, the proposed Merger and related matters. In addition, on September 12, 2022, the Company filed a Current Report on Form 8-K that included certain audited financial statements of Catheter Precision for the two-year period ended December 31, 2021 (the “Catheter Audited Financial Statements”), the unaudited financial

-2-

statements of Catheter Precision for the periods ended June 30, 2022 and June 30, 2021 (the “Catheter Precision Unaudited Financial Statements and together with the Catheter Precision Audited Financial Statements, the “Catheter Precision Financial Statements”), and the unaudited pro forma combined financial information of the combined company as of June 30, 2022 and for the year ended December 31, 2021 and the six months ended June 30, 2022 (the “Pro Forma Financial Information,” and collectively with the Catheter Precision Financial Statements, the “Financial Information”).

Ra Medical intends to mail the Definitive Proxy to Ra Medical stockholders, and Catheter Precision intends to electronically disseminate the PPM/Joint Information Statement. INVESTORS AND SECURITYHOLDERS OF RA MEDICAL AND CATHETER PRECISION ARE URGED TO READ THESE MATERIALS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT RA MEDICAL, CATHETER PRECISION AND THE PROPOSED MERGER. THIS COMMUNICATION IS NOT A SUBSTITUTE FOR THE PPM/JOINT INFORMATION STATEMENT, THE DEFINITIVE PROXY, THE CURRENT REPORTS ON FORM 8-K, INCLUDING THE CURRENT REPORT ON FORM 8-K FILED ON SEPTEMBER 12, 2022, THE COMPANY’S QUARTERLY REPORT FOR THE PERIOD ENDED JUNE 30, 2022, OR ANY OTHER DOCUMENTS THAT RA MEDICAL AND/OR CATHETER PRECISION MAY FILE WITH THE SEC OR SEND TO THEIR RESPECTIVE SECURITYHOLDERS IN CONNECTION WITH THE PROPOSED TRANSACTIONS. INVESTORS AND SECURITYHOLDERS MAY OBTAIN FREE COPIES OF RA MEDICAL’S DOCUMENTS FILED WITH THE SEC, ONCE AVAILABLE, ON THE RA MEDICAL WEBSITE OR ON THE SEC’S WEBSITE.

The unaudited pro forma combined financial information does not purport to represent the actual results of operations that the Company and Catheter Precision would have achieved had the companies been combined during the periods presented in the unaudited pro forma combined financial statements and is not intended to project the future results of operations that the combined company may achieve after the Merger. The unaudited pro forma combined financial information does not reflect any potential cost savings that may be realized as a result of the Merger and also does not reflect any restructuring or integration-related costs to achieve those potential cost savings.

No Offer or Solicitation

This communication is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.

The shares of Common Stock being issued in the Merger (the “Securities”) are being offered and sold in transactions exempt from registration under the Securities Act, in reliance on Section 4(a)(2) thereof. Catheter Precision and Ra Medical intend to distribute a Private Placement Memorandum/Joint Information Statement (the “PPM/Joint Information Statement”) to the stockholders of Catheter Precision, and Catheter Precision stockholders are encouraged to carefully read the PPM/Joint Information Statement, together with Ra Medical’s SEC filings, which will contain important information concerning the transaction.

The Securities have not been registered under the Securities Act and such Securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state securities laws.

Participants in the Solicitation

Catheter, the Company, and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of the Company in connection with the proposed transaction. Information about the Company’s directors and executive officers is set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 which was filed with the SEC on March 24, 2022, the Company’s definitive proxy statement for its annual meeting of stockholders filed on April 21, 2022, and in subsequent filings made by the Company with the SEC. OTHER INFORMATION REGARDING THE INTERESTS OF SUCH INDIVIDUALS, AS WELL AS INFORMATION REGARDING CATHETER’S DIRECTORS AND EXECUTIVE OFFICERS AND OTHER PERSONS WHO MAY BE DEEMED PARTICIPANTS IN THE PROPOSED TRANSACTION, WILL BE

-3-

SET FORTH IN THE DEFINITIVE PROXY AND OTHER RELEVANT MATERIALS TO BE FILED WITH THE SEC WHEN THEY BECOME AVAILABLE. YOU MAY OBTAIN FREE COPIES OF THESE DOCUMENTS AT THE SEC’S WEBSITE AT WWW.SEC.GOV, ON RA MEDICAL’S INVESTOR RELATIONS WEB PAGE AT HTTPS://IR.RAMED.COM/.

Cautionary Note Regarding Forward-Looking Statements

This communication contains forward-looking statements which include, but are not limited to, statements regarding expected timing, completion and effects of the proposed Merger, future access to capital markets, and the plans and expectations of the combined company regarding Catheter’s products, including its plans, strategies, projected timelines and estimated markets, for and/or related to VIVO and the Amigo and vessel closure devices described in the exhibits hereto. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties related to: the ability of the parties to consummate the proposed Merger, satisfaction of closing conditions precedent to the consummation of the proposed Merger, potential delays in consummating the Merger and the ability of the Company to timely and successfully achieve the anticipated benefits of the Merger, including the ability of the combined company to access the capital markets at such times and in such amounts, and on such terms, as needed to meet the Net Cash requirements of the Merger Agreement, execute its future business strategies and maintain its listing on the NYSE American or other national stock exchange, potential application of SEC and/or exchange “shell company” rules, and the ability of the combined company to successfully pursue its product lines in the manner and in the timeframe described here. The Merger Agreement contains certain closing conditions, including a minimum prevailing stock price for Ra Medical and Net Cash amount at closing, which do not constitute representations or covenants of either party, and are subject to waiver by the parties. If Ra Medical’s stock price drops below certain levels, the amount of merger consideration, if any, received by Catheter stockholders will be adversely impacted. The parties have reserved the right to waive conditions to the closing of the Merger, including the stock price condition, and revise the Merger Agreement. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption “Risk Factors” and elsewhere in the Company’s most recent filings with the SEC, including the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, Exhibits 99.7 and 99.8 attached to the Company’s Preliminary Proxy Statement filed on September 23, 2022, as amended on November 4, 2022, Current Report on Form 8-K filed on September 12, 2022, and any prior or subsequent reports on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to time and available at www.sec.gov. Important business and financial information about Catheter’s business and the related discussion and analysis of financial condition and results of operations of Catheter are described in “Catheter Precision Summary Business Description,” included as Exhibit 99.2 to the Company’s Current Report on Form 8-K filed on September 12, 2022, and “Catheter Precision Management’s Discussion and Analysis,” included as Exhibit 99.3 to the Company’s Current Report on Form 8-K filed on September 12, 2022, and in the Company’s Preliminary Proxy Statement filed on September 23, 2022, as amended on November 4, 2022. This information should be read in conjunction with certain audited financial statements of Catheter for the two-year period ended December 31, 2021 (the “Catheter Precision Audited Financial Statements”), the unaudited financial statements of Catheter for the periods ended June 30, 2022 and June 30, 2021 (the “Catheter Precision Unaudited Financial Statements and together with the Catheter Precision Audited Financial Statements, the “Catheter Precision Financial Statements”), and the unaudited pro forma combined financial information of the combined company as of June 30, 2022 and for the year ended December 31, 2021 and the six months ended June 30, 2022 (the “Pro Forma Financial Information,” and collectively with the Catheter Financial Statements, the “Financial Information”), which were filed as Exhibit 99.4, Exhibit 99.5, and Exhibit 99.6 to the Company’s Current Report on Form 8-K filed on September 12, 2022, respectively. Risks and uncertainties related to the Merger, Catheter, and the projections and estimates described in the exhibits hereto that may cause actual results to differ materially from those expressed or implied in any forward-looking statement are described in “Risk Factors -- Risks Related to the Merger with Catheter Precision and – Risks Related to Our Evaluation of Strategic Alternatives for our Legacy Assets,” and “Risk Factors – Risks Related to the Business of Catheter Precision,” which were filed as Exhibit 99.7 and Exhibit 99.8 to the Company’s Current Report on Form 8-K filed on September 12, 2022, respectively, and in the Company’s Preliminary Proxy Statement filed on September 23, 2022, as amended on November 4, 2022. These documents can be accessed on the Company’s Investor Relations page at https://ir.ramed.com/ by clicking on the link titled “SEC Filings.” The risks and uncertainties may be amplified by the COVID-19 pandemic, which has caused significant economic uncertainty, and ongoing volatility

-4-

in the stock markets and the U.S. economy in general. The extent to which the COVID-19 pandemic impacts the Company’s and Catheter’s businesses, operations, and financial results, including the duration and magnitude of such effects, will depend on numerous factors, which are unpredictable, including, but not limited to, the duration and spread of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume.

The forward-looking statements included in this communication are made only as of the date hereof. The Company and Catheter assume no obligation and do not intend to update these forward-looking statements, except as required by law.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1	Joint Press Release of Ra Medical Systems, Inc. and Catheter Precision, Inc. on November 29, 2022.

104	Cover Page Interactive Data File (formatted as Inline XBRL).

-5-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


		RA MEDICAL SYSTEMS, INC.

Date: November 29, 2022	By:	/s/ Jonathan Will McGuire
		Jonathan Will McGuire Chief Executive Officer (Principal Executive Officer)

-6-

EX-99.1 2 rmed-ex991_7.htm EX-99.1 rmed-ex991_7.htm


	Exhibit 99.1

Catheter Precision’s VIVO™ Systems Used in More Than 20 Procedures at NYU Langone Hospital

MT. OLIVE, N.J. and CARLSBAD, Calif. (November 29, 2022) – Catheter Precision, Inc., a medical device and technology company focused on cardiac electrophysiology, announces the completion of more than 20 procedures at NYU Langone Hospital utilizing the VIVO System that enables physicians to identify the origin of arrhythmias pre-procedure. On September 12, 2022 privately held Catheter Precision announced a definitive merger agreement with Ra Medical Systems (NYSE American: RMED), which, if completed, will result in a combined publicly traded company focusing on the cardiac electrophysiology market.

“Completing the first 20 cases with VIVO at NYU Langone hospital is another milestone demonstrating clinical acceptance of our VIVO system,” said David Jenkins, Catheter Precision CEO. “Continued commercial usage indicates that the physicians believe VIVO provides benefit and we look forward to continuing to draw on their expertise for future growth including product development.”

“Identifying the origins of ventricular arrhythmias can be difficult and time consuming,” said Larry Chinitz, Director of electrophysiology and the Heart Rhythm Center at NYU Langone. “VIVO has enabled us to rapidly identify the targeted ablation area and provide additional insight into the patient’s unique anatomy and arrythmia more rapidly. In addition to saving procedural time, combining all of this data in advance of the procedure has potential benefits for better treatment outcomes.”

Catheter Precision’s lead product, VIVO™ (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has been awarded the CE mark. The company also intends to pursue a second generation of Amigo®, a previously FDA-cleared and CE mark robotic arm that can be used to remotely control catheters outside of the procedure room. Additionally, Catheter Precision is working toward a commercial launch of a vessel closure device, currently planned for the first half of 2023.

Under the terms of the definitive merger agreement with Ra Medical Systems, Catheter Precision will become a wholly owned subsidiary of Ra Medical Systems in a stock-for-stock reverse merger transaction. The merger is expected to close in the fourth quarter of 2022 or the first quarter of 2023, subject to satisfying certain closing conditions, including the receipt of required shareholder approval.

About Catheter Precision

Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

Additional Information and Where to Find It

19046793v1

The Merger is currently expected to close before the end of 2022 or during the first quarter of 2023, subject to satisfying certain closing conditions, including the receipt of shareholder approval by both companies. The descriptions of the Merger, the proposals to be voted on in connection with the Merger at the Ra Medical Special Meeting of Stockholders, Catheter and the other transactions and matters contemplated thereby that are referenced herein do not purport to be complete and are qualified in their entirety by reference to the Company’s Reports filed with the Securities and Exchange Commission (“SEC”), including the Current Reports on Form 8-K filed on September 12, 2022 and September 2, 2022, the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2022 and any prior or subsequent reports on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to time and available on the SEC website, as well as the Company’s preliminary proxy statement relating to the Merger with Catheter Precision that was filed with the SEC on September 23, 2022, as amended on November 4, 2022, as further described below.

This communication relates to the proposed Merger involving Catheter and the Company and may be deemed to be solicitation material in respect of the proposed transaction. In connection with the proposed Merger between Catheter and the Company, on September 23, 2022, the Company filed a preliminary proxy statement with the SEC, as amended on November 4, 2022, and intends to file a definitive proxy statement (the “Definitive Proxy”) to call, give notice of and hold a meeting of its stockholders to vote to approve, among other matters, (a) the Merger, and (b) the issuance of the shares of the Ra Medical Common Stock to be issued pursuant to the terms of the Merger Agreement. This communication is not a substitute for the Definitive Proxy or any other documents that the Company may file with the SEC or send to the Company’s stockholders in connection with the proposed transaction. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITYHOLDERS ARE URGED TO READ THE DEFINITIVE PROXY AND ALL OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. INVESTORS AND SECURITY HOLDERS MAY OBTAIN FREE COPIES OF THESE DOCUMENTS (WHEN THEY ARE AVAILABLE) AND OTHER RELATED DOCUMENTS FILED WITH THE SEC AT THE SEC’S WEBSITE AT WWW.SEC.GOV ,AND ON RA MEDICAL’S INVESTOR RELATIONS WEB PAGE AT HTTPS://IR.RAMED.COM/.

The Definitive Proxy and PPM/Joint Information Statement will contain important information about Catheter Precision, the proposed Merger and related matters. In addition, on September 12, 2022, the Company filed a Current Report on Form 8-K that included certain audited financial statements of Catheter Precision for the two-year period ended December 31, 2021 (the “Catheter Audited Financial Statements”), the unaudited financial statements of Catheter Precision for the periods ended June 30,

2022 and June 30, 2021 (the “Catheter Precision Unaudited Financial Statements and together with the Catheter Precision Audited Financial Statements, the “Catheter Precision Financial Statements”), and the unaudited pro forma combined financial information of the combined company as of June 30, 2022 and for the year ended December 31, 2021 and the six months ended June 30, 2022 (the “Pro Forma Financial Information,” and collectively with the Catheter Precision Financial Statements, the “Financial Information”).

Ra Medical intends to mail the Definitive Proxy to Ra Medical stockholders, and Catheter Precision intends to electronically disseminate the PPM/Joint Information Statement. INVESTORS AND SECURITYHOLDERS OF RA MEDICAL AND CATHETER PRECISION ARE URGED TO READ THESE MATERIALS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT RA MEDICAL, CATHETER PRECISION AND THE PROPOSED MERGER. THIS COMMUNICATION IS NOT A SUBSTITUTE FOR THE PPM/JOINT INFORMATION STATEMENT, THE DEFINITIVE PROXY, THE CURRENT REPORTS ON FORM 8-K, INCLUDING THE CURRENT REPORT ON FORM 8-K FILED ON SEPTEMBER 12, 2022, THE COMPANY’S QUARTERLY REPORT FOR THE PERIOD ENDED SEPTEMBER 30, 2022, OR ANY OTHER DOCUMENTS THAT RA MEDICAL AND/OR CATHETER PRECISION MAY FILE WITH THE SEC OR SEND TO THEIR RESPECTIVE SECURITYHOLDERS IN CONNECTION WITH THE PROPOSED TRANSACTIONS. INVESTORS AND SECURITYHOLDERS MAY OBTAIN FREE COPIES OF RA MEDICAL’S DOCUMENTS FILED WITH THE SEC, ONCE AVAILABLE, ON THE RA MEDICAL WEBSITE OR ON THE SEC’S WEBSITE.

No Offer or Solicitation

Participants in the Solicitation

Cautionary Note Regarding Forward-Looking Statements

“Catheter Precision Summary Business Description,” included as Exhibit 99.2 to the Company’s Current Report on Form 8-K filed on September 12, 2022, and “Catheter Precision Management’s Discussion and Analysis,” included as Exhibit 99.3 to the Company’s Current Report on Form 8-K filed on September 12, 2022, and in the Company’s Preliminary Proxy Statement filed on September 22, 2022, as amended on November 4, 2022. This information should be read in conjunction with certain audited financial statements of Catheter for the two-year period ended December 31, 2021 (the “Catheter Precision Audited Financial Statements”), the unaudited financial statements of Catheter for the periods ended June 30, 2022 and June 30, 2021 (the “Catheter Precision Unaudited Financial Statements and together with the Catheter Precision Audited Financial Statements, the “Catheter Precision Financial Statements”), and the unaudited pro forma combined financial information of the combined company as of June 30, 2022 and for the year ended December 31, 2021 and the six months ended June 30, 2022 (the “Pro Forma Financial Information,” and collectively with the Catheter Financial Statements, the “Financial Information”), which were filed as Exhibit 99.4, Exhibit 99.5, and Exhibit 99.6 to the Company’s Current Report on Form 8-K filed on September 12, 2022, respectively. Risks and uncertainties related to the Merger, Catheter, and the projections and estimates described above that may cause actual results to differ materially from those expressed or implied in any forward-looking statement are described in “Risk Factors -- Risks Related to the Merger with Catheter Precision and – Risks Related to Our Evaluation of Strategic Alternatives for our Legacy Assets,” and “Risk Factors – Risks Related to the Business of Catheter Precision,” which were filed as Exhibit 99.7 and Exhibit 99.8 to the Company’s Current Report on Form 8-K filed on September 12, 2022, respectively and in the Company’s Preliminary Proxy Statement filed on September 22, 2022, as amended on November 4, 2022. These documents can be accessed on the Company’s Investor Relations page at https://ir.ramed.com/ by clicking on the link titled “SEC Filings.” The risks and uncertainties may be amplified by the COVID-19 pandemic, which has caused significant economic uncertainty, and ongoing volatility in the stock markets and the U.S. economy in general. The extent to which the COVID-19 pandemic impacts the Company’s and Catheter’s businesses, operations, and financial results, including the duration and magnitude of such effects, will depend on numerous factors, which are unpredictable, including, but not limited to, the duration and spread of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume.

CONTACTS:

For Catheter Precision

Missiaen Huck

973-691-2000

mhuck@catheterprecision.com

For Ra Medical Systems

LHA Investor Relations

Jody Cain

310-691-7100
jcain@lhai.com

# # #

GRAPHIC 3 gzwwmdarns2h000001.jpg GRAPHIC begin 644 gzwwmdarns2h000001.jpg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end GRAPHIC 4 gzwwmdarns2h000002.jpg GRAPHIC begin 644 gzwwmdarns2h000002.jpg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end EX-101.SCH 5 rmed-20221129.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 6 rmed-20221129_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 7 rmed-20221129_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 8 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	Nov. 29, 2022
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Nov. 29, 2022
Entity Registrant Name	Ra Medical Systems, Inc.
Entity Central Index Key	0001716621
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity File Number	001-38677
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	38-3661826
Entity Address, Address Line One	2070 Las Palmas Drive
Entity Address, City or Town	Carlsbad
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92011
City Area Code	760
Local Phone Number	804-1648
Written Communications	true
Soliciting Material	true
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.0001
Trading Symbol	RMED
Security Exchange Name	NYSEAMER

XML 9 rmed-8k_20221129_htm.xml IDEA: XBRL DOCUMENT 0001716621 2022-11-29 2022-11-29 false 0001716621 8-K 2022-11-29 Ra Medical Systems, Inc. DE 001-38677 38-3661826 2070 Las Palmas Drive Carlsbad CA 92011 760 804-1648 true true false false Common Stock, par value $0.0001 RMED NYSEAMER true false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.ramed.com/20221129/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports rmed-8k_20221129.htm rmed-20221129.xsd rmed-20221129_lab.xml rmed-20221129_pre.xml rmed-ex991_7.htm http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "rmed-8k_20221129.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "rmed-8k_20221129.htm" ] }, "labelLink": { "local": [ "rmed-20221129_lab.xml" ] }, "presentationLink": { "local": [ "rmed-20221129_pre.xml" ] }, "schema": { "local": [ "rmed-20221129.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "rmed", "nsuri": "http://www.ramed.com/20221129", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "rmed-8k_20221129.htm", "contextRef": "C_0001716621_20221129_20221129", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.ramed.com/20221129/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "rmed-8k_20221129.htm", "contextRef": "C_0001716621_20221129_20221129", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "verboseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ramed.com/20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 16 0001564590-22-038507-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-22-038507-xbrl.zip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end